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Abstract  
Oligodendrocyte precursor cells (OPCs, also called NG2 cells) are scattered throughout brain 
parenchyma, where they function as a reservoir to replace lost or damaged oligodendrocytes, the 
myelin-forming cells. The hypothesis that, under some circumstances, OPCs can actually behave as 
multipotent cells, thus generating astrocytes and neurons as well, has arisen from some in vitro and 
in vivo evidence, but the molecular pathways controlling this alternative fate of OPCs are not fully 
understood. Their identification would open new opportunities for neuronal replace strategies, by 
fostering the intrinsic ability of the brain to regenerate. Here, we show that the anti-epileptic 
epigenetic modulator valproic acid (VPA) can promote the generation of new neurons from NG2+ 
OPCs under neurogenic protocols in vitro, through their initial de-differentiation to a stem cell-like 
phenotype that then evolves to “hybrid” cell population, showing OPC morphology but expressing 
the neuronal marker βIII-tubulin and the GPR17 receptor, a key determinant in driving OPC 
transition towards myelinating oligodendrocytes. Under these conditions, the pharmacological 
blockade of the P2Y-like receptor GPR17 by cangrelor, a drug recently approved for human use, 
partially mimics the effects mediated by VPA thus accelerating cells’ neurogenic conversion. These 
data show a co-localization between neuronal markers and GPR17 in vitro, and suggest that, 
besides its involvement in oligodendrogenesis, GPR17 can drive the fate of neural precursor cells 
by instructing precursors towards the neuronal lineage. Being a membrane receptor, GPR17 
represents an ideal “druggable” target to be exploited for innovative regenerative approaches to 
acute and chronic brain diseases. 
 
 
Keywords  
NG2 cells, GPR17, neurogenesis, valproic acid, oligodendrocyte precursor cells  
 
 
 4	
Introduction 
After embryonic development, quiescent neural stem-like progenitors (NPCs) still persist in 
two brain's neurogenic niches (i.e. the subventricular zone of the lateral ventricles and the 
subgranular layer of the hippocampus) and in central nervous system (CNS) parenchyma 
throughout life (reviewed in [1, 2]). Parenchymal NPCs include subsets of astrocytes, that, when 
activated, re-acquire stem/progenitor cells properties [3], and oligodendrocyte precursor cells 
(OPCs), also known as polydendrocytes, expressing the membrane chondroitin sulphate 
proteoglycan NG2 [1, 4]. NG2-positive cells have been originally identified as the progenitors of 
the myelin-forming cells of the brain and spinal cord (reviewed in [5]) that spontaneously 
differentiate to mature oligodendrocytes both in vitro and in vivo [6]. The hypothesis that OPCs can 
behave as multipotent progenitors was raised after the demonstration that NG2-cells purified from 
early postnatal rat optic nerves have the ability to revert to stem-like cells which eventually 
differentiate to oligodendrocytes, astrocytes and even neurons [7–9]. Afterwards, with the 
development of genetic labeling, transgenic mouse models, in particular those carrying the Cre-loxP 
technology, have become a useful tool for fate-mapping studies to investigate the multipotency of 
these cells in vivo. For example, following brain ischemia due to permanent middle cerebral artery 
occlusion (MCAo), generation of both astrocytic and neuronal precursors from NG2+ cells was 
observed in adult NG2creBAC:ZEG double transgenic mice, in which enhanced green fluorescent 
protein (EGFP) is expressed in OPCs and their progeny, thus allowing to visualize their final 
phenotype [10]. However, conflicting data arise from the different transgenic mouse models 
employed, and the controversy around the multipotency and neurogenic potential of OPCs in vivo is 
still an open issue [11–15]. 
Thus, knowledge of the mechanisms underlying the commitment of OPCs towards either 
myelinating oligodendrocytes or distinct neural lineage is mandatory, but still incomplete. In this 
respect, we have recently focused our attention on the possible role exerted by the P2Y-like 
receptor GPR17, which is closely related to both purinergic P2Y and CysLT receptors [16]. 
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Notably, GPR17 is one of the three genes differentially expressed by human adult hippocampal 
precursor cells when compared to embryonic stem cells [17]. We and others have demonstrated that 
GPR17 is transiently expressed at specific differentiation stages of OPCs, undergoes a tightly 
regulated modulation to drive OPC maturation towards fully mature oligodendrocytes, and 
contributes to their reaction to harmful conditions [18–22]. 
However, while in the intact CNS GPR17 is almost exclusively expressed in OPCs, this 
receptor is rapidly induced in cells of the neuronal lineage inside and at the border of 
ischemic/traumatic lesions in both the MCAo model [16, 23] and in a rodent model of spinal cord 
injury [24]. Moreover, more recent data have shown that GPR17 regulates the proliferation of a 
population of doublecortin (DCX)+ neuronal progenitors (neuroblasts) in hippocampal dentate 
gyrus [25], to suggest that, besides its established role in oligodendrogenesis, GPR17 may also be 
involved in neuronal specification. On this basis, we raised the hypothesis that GPR17 could 
regulate the fate of NPCs addressing them to either the oligodendroglial or the neuronal lineages.  
This work was specifically undertaken to elucidate the possible role of GPR17 in controlling 
the switch of OPCs towards a neurogenic fate. To this aim, we purposely set up two culturing 
protocols known to unveil the multipotency of OPCs in vitro, and we fostered neurogenesis by 
exposing cultures to the epigenetic anti-epileptic agent valproic acid (VPA), known to promote the 
generation of new neurons through inhibition of histone deacetylases in progenitor cells [26–28]. In 
the different experimental conditions, we analyzed the expression of GPR17 and the effect of its 
pharmacological manipulation on cell progeny. Results show, for the first time, the presence of 
GPR17 in a “hybrid” cell population that still bore an OPC morphology but already expressed 
neuronal markers; moreover, blockade of GPR17 by the P2Y antagonist Cangrelor, that also acts as 
an antagonist at GPR17 [16] partially reproduced VPA-mediated increase in neurogenesis, thus 
unveiling a new potential pharmacological approach to shift the cell fate of OPCs towards the 
generation of new neuron-like cells.  
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Materials and Methods 
Primary OPC Cultures  
OPCs were isolated from mixed glial cultures from postnatal day 2 Sprague-Dawley rat 
cortex, by the shaking method [22] followed by immunopurification [29]. This additional step 
consists of a negative selection procedure to remove undesired cells (e.g., astrocytes, meningeal 
cells and microglia/macrophages) by means of the Ran-2 antibody, which does not bind to OPCs 
[30].  
A layer of anti-immunoglobulin antibodies (1 mg/ml anti-IgG, MP Biomedicals, Santa Ana, 
CA) was adsorbed to empty petri dishes the day before culture shaking and incubated overnight at 
4°C, thereby improving the subsequent binding of cell-type specific antibody. The following day, 
mixed cultures were shaken on an orbital shaker for 3-4 hours at 200 rpm. In the meantime, IgG 
coated dishes were rinsed 3 times with PBS and incubated for at least 3 hours at room temperature 
(RT) with a solution containing RAN2 antibody (RAN2-Ab, kindly provided by Prof. Carla 
Taveggia, Axo-Glia Unit, Institute of Experimental Neurology Division of Neuroscience, San 
Raffaele Scientific Institute, Milan) and consisting in 0.5 mL RAN2-Ab + 6 mL of Minimum 
Essential Medium with Earle's salts and L-glutamine (MEM, Life Technologies) + 1 mg/ml Bovine 
Serum Albumin (BSA, Sigma-Aldrich) + 25 mM HEPES pH 7.5 (Sigma-Aldrich). 
At the end of shaking, the medium containing the detached cells was collected from each 
flask in 50 ml sterile conical tubes and centrifuged for 10 min at 290 g. Pellets were resuspended in 
NM15 Medium containing MEM, 15% heat-inactivated fetal bovine serum (FBS, Euroclone), 6 
mg/ml glucose (Sigma-Aldrich), and penicillin–streptomycin (100 U/ml and 100 µg/ml, 
respectively; Euroclone) + insulin (5 µg/ml; Sigma-Aldrich), and the cell suspension was incubated 
at RT in a first RAN2-Ab-precoated plate. After 20 min, floating cells were transferred to a second 
RAN2-Ab-precoated plate and incubated for additional 20 min at RT. The supernatant was then 
collected and centrifuged at 290 g for 10 min. The resulting pellet was resuspended in the 
appropriate medium according to the subsequent protocol (see below). Isolated OPCs were plated 
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onto poly-D,L-ornithine- (final concentration 5 µg/ml; Sigma-Aldrich) coated 13 mm diameter 
glass coverslips (15,000 cells/well) for immunocytochemistry or 35 mm diameter Petri dishes 
(100,000 cells/well) for Western blot analysis. 
To verify whether OPCs can generate neurons under a standard protocol of oligodendrocyte 
differentiation [20, 21, 22], cells were plated in Neurobasal medium with 2% B27 Supplement (both 
from Life Technologies), 2 mM L-glutamine, 10 ng/mL human platelet-derived growth factor BB 
(PDGF-BB, Sigma-Aldrich), and 10 ng/mL human basic fibroblast growth factor (bFGF, R&D 
Systems) to promote proliferation. After 2 days OPCs were shifted to differentiating medium (i.e., 
Neurobasal medium lacking growth factors), and either grown under control conditions or exposed 
to the anticonvulsant agent valproic acid (VPA, 500 µM) for 24-72 hours, fixed and immunostained 
for GPR17 and the neuronal marker βIII-tubulin (see below). 
 
Neurogenic protocols 
To test the ability of OPCs to generate neurons, we applied two published protocols claimed 
to foster OPC transition towards neuroblasts [7, 27]. 
A 3-phases protocol [7] was renamed here as neurogenic protocol #1 (Figure 1a). Cells were 
initially maintained for 5 days in DMEM Medium (consisting in DMEM high glucose 
supplemented with penicillin–streptomycin 100 U/ml and 100 µg/ml, respectively; 1 mM Sodium 
Pyruvate; 2.5 µg/mL Fungizone; 2 mM L-Glutamine; all purchased from Euroclone) +10 ng/ml 
PDGF-BB + B27 supplement (1:50) to induce OPCs proliferation (phase A). Cells were then 
shifted to DMEM Medium + 10 ng/ml PDGF-BB + B27 supplement (1:50) + 15% FBS to promote 
their de-differentiation towards type 2 astrocytes and cultured for 3 days (phase B). Finally, cells 
were maintained for 5 additional days in DMEM Medium + B27 supplement (1:50) +10 ng/ml 
basic fibroblast growth factor (bFGF, R&D) to induce their differentiation along the three neural 
lineages (phase C).  
 8	
We then set up an additional neurogenic protocol, renamed here as neurogenic protocol #2 
(Figure 1b; [27]). Cells were exposed for 2 days to Proliferation Medium (i.e., DMEM Medium + 
10 ng/ml PDGF-BB + 10 ng/ml bFGF +	B27 supplement (1:50); phase PM) and then committed to 
differentiate into oligodendrocytes by removing mitogens for 1 day (Differentiation Medium; phase 
DM). Finally, cells were cultured in Stem Cell Medium composed by DMEM/F-12 (Life 
Technologies), Glutamine (1 mM), Glucose (25 mM, Sigma-Aldrich) and B27 supplement (1:50) 
for 3 days (phase SCM), which directly redirect OPCs to the three neural lineages [27]. 
In both protocols, at the end of the different phases either cells were fixed with 4% 
paraformaldehyde and processed for immunocytochemistry or whole-cell lysates were prepared and 
analyzed by Western blotting (see Results and Figures). 
 
Pharmacological treatments 
In either neurogenic protocol, we have verified if and how the exposure to various 
pharmacological agents (including GPR17 receptor ligands) can modulate OPCs plasticity and their 
differentiation to neurons. In particular, we have utilized the non-selective GPR17 agonist UDP-
glucose (UDP-glc; 100 µM [16, 20–23, 31–34]) and antagonist Cangrelor (Cang; 10 µM), in 
parallel to VPA (500 µM). All reagents were obtained from Sigma-Aldrich, except for Cangrelor 
that was a kind gift of The Medicines Company (Parsippany, NJ, USA). In neurogenic protocol #1 
cells were treated with the different pharmacological agents during phase C only, whereas in 
neurogenic protocol #2 cells were treated during both phase DM and SCM (see Figure 1a, b). 
 
Immunocytochemistry, image processing and data analysis 
Fixed cells were subjected to immunocytochemistry as previously described [20]. The 
following antibodies and final dilutions were used: primary antibodies: rabbit anti-GFAP (1:600, 
Dako Italia, Cernusco sul Naviglio, Milan, Italy), mouse anti-βIII-tub (1:1,000; Promega, Milan, 
Italy), mouse anti-NG2 (1:200; Abcam, Cambridge, UK), and rabbit anti-GPR17 (1:100; Cayman 
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Chemical Company, Ann Arbor, MI); secondary antibodies: goat anti-rabbit or goat anti-mouse 
antibodies conjugated to AlexaFluor®488 or AlexaFluor®555 (all 1:600, 1 hour at RT; Life 
Technologies). Nuclei were then labeled with the fluorescent dye Hoechst-33258 (1:10,000 in PBS; 
Life Technologies) and coverslips were mounted in Dako Fluorescence Mounting Medium (Dako).  
Cells were finally analyzed by a fluorescent microscope (Zeiss, Jena, Germany). In each 
coverslip, the total number of cells, evaluated by counting Hoechst-33258+ nuclei, and the number 
of GPR17-, βIII-tubulin, GFAP- or NG2-positive cells were determined in 20 randomly chosen 
optical fields under a 40x magnification. The total number of cells counted for each experimental 
condition was between 300 and 500.  
To evaluate the intensity of GPR17 staining in OPCs cultured in standard differentiating 
conditions, fluorescent images were captured under a Zeiss Axiovert 200M microscope (Carl Zeiss) 
equipped with a CCD camera module at 40x magnification. Densitometric analysis was performed 
after converting the fluorescent signals to gray-scale values. The mean gray value in 10 randomly 
chosen optical field/coverslip was measured by the ImageJ software.  
 
Western-blotting analysis 
Whole-cell lysates were prepared and analyzed by Western blotting as previously described 
[35]. Cell pellets were homogenized on ice in lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM 
EDTA, 0.5% sodium deoxycholate, 1% Triton, 0.1% SDS) added with 1:100 protease inhibitor 
cocktail (Sigma-Aldrich). Thirty µg aliquots from each protein sample were loaded on 11% 
sodium-dodecylsulphate polyacrylamide gels, and blotted onto nitrocellulose or PVDF membranes 
(Bio-Rad Laboratories, Milan, Italy). Membranes were then saturated with 10% non-fat dry milk in 
Tris-buffered saline (TBS; 1 mM Tris-HCl, 15 mM NaCl, pH 8) for 1 hour at RT, and incubated 
overnight at 4°C with mouse anti-synaptic vesicle2 (SV2, 1:2,000) and anti-βIII-tub (1:1,000, 
Promega, Milan, Italy) or rabbit anti-synaptotagmin (Syt, 1:2,000; anti-SV2 and anti-Syt are a kind 
gift of Dr. C. Verderio, CNR, Milan), anti-CNPase (1:250, Santa Cruz), and anti-GPR17 primary 
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antibodies (1:100; home-made polyclonal antibody from Dr. Patrizia Rosa, CNR, Milan) all in 5% 
non-fat dry milk in TBS. Membranes were then washed in TBS-T (TBS plus 0.1% Tween20®), 
incubated for 1 h with goat anti-rabbit or anti-mouse secondary antibodies conjugated to 
horseradish peroxidase (1:4,000 or 1:2,000, respectively in 5% non-fat dry milk in TBS; Sigma-
Aldrich). Detection of proteins was performed by enhanced chemiluminescence (ECL, Amersham 
Biosciences, Milan, Italy) and autoradiography. Non-specific reactions were evaluated in the 
presence of the secondary antibodies alone. 
 
Luciferase reporter assay  
For the analysis of promoter induction, the Oli-neu murine cell line was cultured in Sato 
medium containing 1% horse serum). The day after seeding, cells were transfected with a reporter 
construct containing an active region of the human GPR17 promoter, as previously described [36]. 
Exposure to 1 mM VPA was started the following day and lasted 48 h. The Dual Luciferase 
Reporter Assay (Promega) was performed according to the manufacturer’s instructions. 
 
Statistical analysis  
Data were analyzed using the GraphPad Prism5 software. Differences between experimental 
conditions were calculated using either unpaired two-tailed Student's t test, or one-way ANOVA 
followed by the Bonferroni’s post-hoc test. A p value <0.05 was considered as significant. 
 
Results 
NG2+ OPCs are multipotent cells, and their multipotency is unveiled by specific neurogenic 
protocols. 
When cultured in differentiating conditions, NG2+ OPCs progressively maturate to 
myelinating oligodendrocytes [20–23]. To verify whether their intrinsic multipotency can be 
unveiled under these standard culturing conditions, we isolated rat OPCs from mixed cortical glial 
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cell cultures, grew them for 24-72 hours under control (CTR) conditions or in the presence of 500 
µM VPA (an antiepileptic agent known to stimulate neurogenesis by inhibiting histone 
deacetylases; [26–28]), and counted the number of βIII-tubulin (βIII-tub)+ cells. 
Very few βIII-tub+ cells were observed at any of the time points tested either in CTR 
cultures or following exposure to VPA (Figure 2a), with a trend to decrease with time in culture. 
When this cell population was evaluated as percentage of the total number of cells (Figure 2b), 
values between 0.60% and 0.35% were obtained (Figure 2c), thus suggesting that these culturing 
conditions are not able to switch OPCs from their oligodendrocyte fate to a neurogenic one, not 
even in the presence of a known pro-neurogenic agent like VPA. Thus, to unmask the latent ability 
of OPCs to generate neurons, we grew them according to two protocols, renamed here neurogenic 
protocol #1 [7] and neurogenic protocol #2 ([27]; see Materials and Methods and Figure 1). At the 
end of each phase we performed immunocytochemical analysis to characterize the composition of 
the cell population. 
Concerning protocol #1, at the end of phase A the majority of cells were NG2+ OPCs, while 
only few GFAP+ astrocytes were observed (Figure 3; see histograms in a and representative picture 
in b). A significant population of cells expressed GPR17 (Figure 3a), with more than 60% of 
GPR17+ cells also coexpressing NG2, thus confirming that the receptor decorates a subpopulation 
of early OPCs (Figure 3b) in line with our already published results [20–22]. At the end of phase B, 
cells de-differentiated to multipotent and undifferentiated precursors characterized by strong GFAP 
immunoreactivity and branched morphology (Figure 3c). Moreover, expression of both NG2 and 
GPR17 was dramatically down regulated compared to phase A (Figure 3a). At the end of the last 
phase (phase C), that re-addresses GFAP+ undifferentiated precursors to all the three neural 
lineages, the majority of the cell population is represented by OPCs re-expressing NG2 and GPR17, 
whereas the number of GFAP+ cells was decreased compared to phase B (Figure 3a,b). 
Interestingly, we also observed a trend to increase in the number of βIII-tub+ neuron-like cells 
(Figure 3e; example picture in d), thus demonstrating that neurogenic protocol #1 succeeded in 
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addressing a subpopulation of undifferentiated GFAP+ precursors towards a neuronal fate. In 
agreement with literature data, βIII-tub+ neuron-like cells showing a bipolar shape (Figure 3d) never 
co-expressed either NG2 (see split fluorescence channels in Supplementary Figure 1) or GPR17 
(see also below). 
We next characterized the progeny of OPCs grown under neurogenic protocol #2 after one 
day in DM or three days in SCM (see Materials and Methods; Figure 1). Also this protocol was able 
to unveil the multipotency of OPCs and to redirect NG2+ cells also towards a neuronal fate, as 
demonstrated by a significant increase in the number of βIII-tub+ neuron-like cells at the end of 
SCM phase compared to the end of phase DM (Figure 4a). In parallel, the number of NG2+ cells 
decreased significantly when cells were shifted to SCM suggesting that at least a fraction of these 
cells were re-addressed towards a different fate. The number of GPR17-expressing cells was instead 
similar at the end of both phases (Figure 4b), with the vast majority of the GPR17+ cells being 
NG2-expressing OPCs at the end of incubation in DM (Figure 4c), as expected. 
 
Valproic acid implements the neurogenic potential of OPCs and modulates the expression of 
GPR17. 
We then verified if and how exposure to VPA (500 µM) and to purinergic receptor ligands 
targeting GPR17 could modulate OPC multipotency and their commitment towards neurons with 
either neurogenic protocol. We chose a GPR17 antagonist (Cang; 10 µM), and a GPR17 agonist 
(UDP-glc; 100µM  [16, 20–23, 31–34]). In neurogenic protocol #1 cells were treated with the 
different pharmacological agents during phase C only, whereas in neurogenic protocol #2 cells were 
treated during both phase DM and SCM (see Figure 1 and Materials and Methods for details). 
Exposure to VPA led to a significant increase in the total number of βIII-tub+ cells at the end 
of both neurogenic protocols, in parallel to a reduction in the number of GPR17+ cells (Figure 5a). 
No differences were instead observed between control and VPA-treated cells in the expression of 
the OPC marker NG2 (data not shown).  
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To further confirm the neuronal commitment of OPCs, we performed Western blot analysis 
on cell lysates from CTR and VPA-treated cultures at the end of phase C (neurogenic protocol #1; 
Figure 5b, left) or phase SCM (neurogenic protocol #2; Figure 5b, right). Increase in βIII-tub and 
decrease in GPR17 expression were observed with either neurogenic protocol, thus fully confirming 
data from immunocytochemistry, and suggesting an attempt of OPCs to escape from their 
“classical” oligodendrocyte fate. In neurogenic protocol #2, we also investigated the expression of 
two neuronal synaptic proteins (namely, synaptic vesicles 2, SV2 and synaptotagmin, syt). VPA 
induced a marked increase in SV2 expression compared to control cells, whereas Syt expression 
was unaffected (Figure 5b, right). Taken together, our results confirm that VPA stimulates the 
differentiation of OPCs toward cells committed to neuronal differentiation, as suggested by the 
presence of synaptic vesicle proteins. 
Interestingly, when primary rat OPCs were grown in standard differentiating conditions in 
the presence of VPA for 24 hours, we also observed a reduction of GPR17 expression compared to 
control cultures (Figure 5c), despite no changes in the generation of new neuron-like cells (see 
Figure 2). This suggested us that VPA could have a direct action on GPR17 promoter, which is 
independent from its pro-neurogenic activity. Thus, to verify whether VPA directly influences 
GPR17 expression, we transfected the immortalized murine oligodendroglial Olineu cell line with a 
reporter construct in which an active portion of the GPR17 promoter had been previously cloned. In 
this reporter assay, VPA showed an inhibitory effect on GPR17 promoter activity compared to the 
empty vector (Figure 5d). Overall, these data suggest that VPA can modify GPR17 expression in 
OPCs cells by directly acting on its promoter sequence. 
Concerning the effects of the pharmacological modulation of GPR17, using neurogenic 
protocol #1, we observed a significant increase in the number of βIII-tub+ cells after exposure to 
Cang (Figure 5e), whereas UDP-glc exerted no effect. Conversely, in neurogenic protocol #2 the 
number of βIII-tub expressing cells seemed to be unaffected by either GPR17 ligand (Figure 5f). 
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Exposure to either Cang or UDP-glc did not modify the number of GPR17-expressing cells 
in both neurogenic protocol #1 (Figure 5e), and neurogenic protocol #2 (Figure 5f). Thus, under the 
culturing conditions of neurogenic protocol #1 blockade of GPR17 receptor facilitates the 
neurogenic progression of OPCs, whereas receptor activation with UDP-glc exerts no effect. 
 
Exposure to Cangrelor or VPA increases the percentage of GPR17+ cells coexpressing βIII-
tubulin 
Two morphologically distinct groups of βIII-tub+ cells were observed at the end of both 
neurogenic protocols: the first showed a typical bipolar neuroblast shape probably representing 
immature neurons (see above; arrow in Figure 3d), whereas the second and more abundant type of 
cells still bore an OPC-like morphology (arrows in Figure 6). As already mentioned above, in 
agreement with literature data, the former cell population never expressed GPR17. Conversely, in 
the latter cell population, a fraction of βIII-tub/GPR17 double-positive cells was detected already 
under CTR conditions at the end of phase C and of phase SCM (Figure 6a, b). This is particularly 
interesting since no colocalization of GPR17 with neuronal markers has ever been observed in vitro. 
The “hybrid” βIII-tub/GPR17 double-positive cell population was not detected in the early phases 
of either neurogenic protocol, and may represent an intermediate precursor stage preceding the 
neuronal stage at which GPR17 is downregulated. Re-expression of GPR17 at this intermediate 
stage suggests that, in a subset of precursors and under specific neurogenic conditions, this receptor 
may contribute to drive precursors cells to a neuronal destiny.  
 On this premises, we analyzed the effects of the above-mentioned pro-neurogenic 
pharmacological treatments on the population of GPR17/βIII-tub double-positive cells under both 
neurogenic protocols. In neurogenic protocol #1, the percentage of GPR17/βIII-tub double-positive 
cells over the total cell population (evaluated by counting Hoechst-33258+ cell nuclei) was similar 
in control cultures or after exposure to UDP-glc (100 µM; control: 3.10±1.29%, UDPglc: 
2.76±0.89%; 20 optical fields from 3 coverslips/condition), whereas it increased in cultures treated 
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with either Cang (10 µM; control: 2.39±0.62%, Cang: 4.92±1.00%; p<0.05 unpaired two-tailed 
Student's t test; 20 optical fields from 3 coverslips/condition) or VPA (500 µM; control: 
2.39±0.62%,VPA: 5.38 ±1.24%; p<0.05 unpaired two-tailed Student's t test; 20 optical fields from 
3 coverslips/condition). An even more pronounced effect was observed when considering the 
percentage of GPR17/βIII-tub double-positive cells over the total number of GPR17+ cells, which in 
VPA- and Cang-treated cultures was three times and about twice as high as in CTR cultures, 
respectively. No changes were observed with UDP-glc (Figure 6a, c). With neurogenic protocol #2, 
at the end of phase SCM, a trend to increase in the percentage of GPR17/βIII-tub double-positive 
cells over the total number of GPR17+ cells was observed after exposure to VPA (Figure 6b, d). 
Conversely, if the population of GPR17/βIII-tub double-positive cells is expressed as % of 
the total number of βIII-tub+ cells, no changes were observed upon the various pharmacological 
treatments (Figure 6e, f). This further confirms that the observed effects are related to an action on 
GPR17, since either pharmacological treatment have no effect on the 60-70% of βIII-tub+ cells that 
do not express the receptor. 
Upon exposure to either VPA or Cang we also observed a trend to a decrease in the 
percentage of NG2/GPR17 double-positive cells calculated on the total number of cells (CTR: 
23.28±10.85%, VPA: 8.73±2.11 and Cang: 8.49±2.92%, 20 optical fields from 3 
coverslips/condition), thus confirming that a subset of OPCs is shifting its fate from 
oligodendrocytes to neurons. Nevertheless, GPR17/NG2 double-positive cells still represented the 
majority of the GPR17+ cell population (control: 58.56±15.75%, VPA: 45.62±8.40, Cang: 
55.10±18.33%, 20 optical fields from 3 coverslips/condition).  
Taken together our results suggest that VPA and, to a lesser extent Cang, are able to select a 
population of “hybrid” cells with an OPC morphology that starts acquiring neuronal markers and 
expresses GPR17. 
 
Discussion 
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The main results of the present paper are: (i) under specific neurogenic conditions in vitro, the 
transition from OPCs to cells of the three neural lineages is accompanied by appearance of an 
“hybrid” cell population, showing typical OPC morphology but expressing the neuronal marker 
βIII-tub; (ii) interestingly, this new cell population also co-expresses GPR17, already known to 
stimulate OPC differentiation towards fully myelinating oligodendrocytes; (iii) exposure of de-
differentiated precursors to Cangr, a GPR17 antagonist, partially mimics the effects mediated by the 
anti-epileptic epigenetic agent VPA and accelerates cells’ neurogenic conversion. These data show 
for the first time a co-localization between neuronal markers and GPR17 in vitro. Moreover, they 
extend the role of GPR17 in driving the fate of neural precursor cells, suggesting that, besides its 
involvement in oligodendrogenesis, this receptor may also instruct precursors to the neuronal 
lineage. 
 
In vitro generation of βIII-tub+ cells from NG2+ OPCs. 
Our initial experiments demonstrate that a very low percentage of βIII-tub+ cells is detected 
when OPCs are cultured in standard conditions, which are known to promote their maturation 
towards myelinating oligodendrocytes [20–23], even in the presence of the neurogenic agent VPA 
(Figure 2; see also below). Besides, the trend to a reduction of their number over time in culture 
suggests that these cells could represent contaminating neurons surviving from the original mixed 
glial cell cultures. 
Thus, we cultured NG2+ OPCs according to a 3-phase protocol, renamed here neurogenic 
protocol #1 [7], leading to their initial regression to an intermediate multipotent stage characterized 
by massive expression of GFAP (phase B) with no NG2 staining, which was then followed by 
GFAP downregulation, re-appearance of NG2 and, most important, acquisition of the typical 
neuronal marker βIII-tub (phase C; Figure 3). Interestingly, these phenotypic shifts were 
accompanied by significant changes of GPR17 expression, which was, as expected, highly 
expressed in NG2+ cells but disappeared in the intermediate de-differentiated GFAP+ cells (Figure 
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3). This is in line with our previous in vivo and in vitro observations showing no colocalization of 
GPR17 with astrocytic markers [16, 23, 24], and demonstrating that GPR17 specifically decorates a 
subpopulation of early NG2+ OPCs [20–22, 24]. A similar pattern of GPR17 co-localization with 
NG2 (Figure 4) was observed with neurogenic protocol #2, which lacks the intermediate stage of 
cell de-differentiation to GFAP+ precursors, but unveils OPC multipotency thanks to the exposure 
to a defined SCM known to support stem cell growth ([27, 37]; Figure 1) 
At the end of both protocols, the increased expression of the neuronal marker βIII-tub 
confirms that multipotency in vitro is an intrinsic feature of a subpopulation of NG2+ OPCs. These 
results emphasize the notion that postnatal OPCs can no longer be considered as mere progenitors 
restricted to an oligodendroglial fate [38], but are indeed stem-like cells that can unveil their 
multipotency under specific conditions. This is also confirmed by the in vivo demonstration that, 
upon injury, adult parenchymal OPCs are reverted to an immature phenotype that more closely 
resembles that of neonatal OPCs [39]. 
 
Valproic acid fosters the neuronal commitment of OPCs and modulates GPR17 expression. 
As already shown in literature [40], our data show that the above-mentioned neurogenic shift 
is markedly implemented by exposure to VPA (500 µM), an anti-epileptic drug known to act as 
HDAC inhibitor ([41]; Figure 4). In particular, VPA increased the expression of the neuronal 
marker βIII-tub, in parallel with an higher expression of synaptic vesicle protein 2 (SV2), an 
integral membrane protein expressed in synaptic vesicles [42, 43], suggesting commitment of OPCs 
towards neuroblasts that are acquiring proteins typically involved in synaptic transmission.  
VPA treatment itself is not enough to induce OPCs to express βIII-tub under standard 
differentiating conditions (Figure 2), but, nevertheless, VPA significantly reduced GPR17 
expression even under these conditions (Figure 5c), suggesting a direct effect of the drug on GPR17 
expression.  This effect is more evident when VPA is added to either neurogenic protocol (Figure 
5a, b), in line with the notion that inhibition of HDACs reduces the expression of genes driving 
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oligodendrocyte specification [26–28]. Our reporter assay (Figure 5d) also suggests that VPA 
inhibits GPR17 expression by likely regulating transcription factors that activate the GPR17 
promoter, such as Olig1 or FoxO1 [18, 23, 44, 45], thus disrupting the balance between 
oligodendroglial commitment and stemcellness.  
Despite being mostly expressed by NG2+ cells, under neurogenic culturing conditions GPR17 
was surprisingly expressed by a subset of βIII-tub+ cells whose number was increased by exposure 
to VPA up to more than 25% of the total number of GPR17-expressing cells (Figure 6). This cell 
population showed the typical highly branched morphology of OPCs, thus probably representing a 
sort of “hybrid” of differentiation that is intermediate between the oligodendrocyte and neuronal 
fates. Thus, besides being a trigger for oligodendroglial differentiation [21], the P2Y-like receptor 
GPR17 may also be involved in the neurogenic specification of OPCs. This was already suggested 
by previous findings [46] that highlighted a role for GPR17 in the neuronal differentiation of PC12 
cells, via modulation of the effects induced by classical growth factors. It is worth mentioning that 
GPR17 expression was not observed on βIII-tub+ cells displaying typical neuroblast morphology 
(see arrow in Figure 3D), suggesting that GPR17 expression in these precursors is transient and that 
the receptor is downregulated at later stages of neuronal differentiation. It may well be that GPR17 
participates to neuronal specification during development, is turned down during adulthood, and is 
then re-activated under disease conditions, when endogenous reparative neurogenesis is switched 
on, as suggested by increased neuronal expression of GPR17 in the ischemic rat and mouse brain 
[16, 23], as well as in the injured spinal cord after a mechanical insult [24]. Alternatively, despite 
not being normally expressed in adult neurons, GPR17 may be involved in the formation of new 
neuronal cells in some specific brain areas where neurogenesis is preserved throughout adulthood, 
such as, for example, the hippocampus during learning and memory processes. In this respect, we 
have recently shown that GPR17 regulates the proliferation of a subpopulation of hippocampal 
doublecortin (DCX)+ neuronal progenitors involved in cognitive performances ([25]; see also 
below). 
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It has already been demonstrated that the systemic administration of VPA in rodents is 
associated with a reduction of oligodendrocyte generation and a corresponding increase of 
astrocytes and neurons [27]. Moreover, having been utilized in clinics as anti-epileptic [47], anti-
migraine [48] and anti-maniac drug [49] for years, VPA profile in patients is rather well known, 
which could accelerate the translation of data to humans also for its use in other brain diseases. 
However, these very exciting perspectives must be confronted with the potential drawbacks linked 
to the high number of genes regulated through VPA-mediated mechanism [41].  
 
Antagonism of GPR17 promotes the neurogenic transition of NG2+ precursors. 
Our current data show that increased neurogenesis was also observed by exposing cultures to 
the Cang, acting as a GPR17 antagonist, whereas no changes were detected with UDP-glc (Figures 
5, 6). Experiments were characterized by high variability, which is possibly linked to the use of 
heterogeneous primary cultures that are composed of non-synchronized cells at different stages of 
differentiation, and characterized by a different rate of proliferation, and by the application of 
complex, multistep neurogenic protocols. Thus, while the effect of VPA is very consistent due to its 
broad epigenetic mechanism, the variability observed upon GPR17 blockade can be explained with 
the transient expression of this membrane receptor during the whole differentiation program [19–
22]. On the other hand, to explain the lack of significant effects by UDP-glc, cultured cells may 
themselves release endogenous GPR17 agonists that tonically regulate this receptor in vitro, thus 
making it difficult to unveil the effects mediated by exogenously-added compounds. Nevertheless, 
the present data showing implementation of the neurogenic fate by Cang are in strong agreement 
with our previous data on hippocampal GPR17 expressing DCX precursors, where receptor 
blockade with another antagonist, montelukast [16, 23] markedly increased the number of new 
mature neurons in parallel with increased animals’ cognitive abilities [25].  
In the present study, the more interesting and consistent results have been obtained with 
neurogenic protocol #1. This is possibly due to the fact that, at variance from protocol #2, this 
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protocol involves the de-differentiation of NG2+ progenitors to GFAP+ multipotent cells (phase B), 
which are likely more prone to undergo epigenetic and pharmacological modulation towards a 
neuronal progeny. Nevertheless, the overall major length of protocol #1 compared to protocol #2 
(13 vs. 6 days, respectively) poses technical problems for future experiments aimed at further 
fostering neurogenesis by prolonging cell exposure to either VPA or Cang. At the end of protocol 
#1, in fact, cells start showing signs of suffering and death (not shown) due to the length of time in 
culture. However, these results build up the background for further analysis, for the set-up of 
pharmacological/biotechnological approaches preventing excessive tissue degeneration while 
enhancing local reparative mechanisms. Importantly, GPR17 is a membrane receptor, thus 
amenable for activation/blockade by signals present in the local CNS milieu and for exogenous 
regulation by drugs, at variance from protocols based on genetic manipulations which are less prone 
to clinical exploitation, due to important drawbacks, such as the potential to cause tumor growth 
and gene mutations. In this respect, the pharmacological manipulation of endogenous cells still 
represents a safer and useful strategy for possible clinical applications. It is worth mentioning that 
the in vivo treatment of ischemic animals with Cang markedly prevented brain damage evolution 
[16, 23], suggesting a protective role against injury development. However, Cangr acts also as a 
potent antagonist at the P2Y12 receptor subtype which has been shown to be highly expressed in the 
megakaryocyte/platelet lineage [50]. In this respect, FDA has recently approved it (June 2015) as an 
antiplatelet agent for intravenous application. The present findings unveiling the neurogenic 
properties of Cangr are particularly interesting in view of strategies aimed at repurposing this drug 
for additional neuroprotective uses that could be envisaged to speed up the development of urgently 
needed medicines for these patients. 
Overall, based on the well-known role of purinergic signaling in regulating the synchronized 
proliferation, migration, differentiation and death of embryonic and adult NPCs [51-54] , our 
present results strengthen the evidence that the purinergic system crucially regulates neuronal 
progenitors also in brain parenchyma, outside the well-known neurogenic niches. The 
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pharmacological modulation of the purinergic system could therefore represent a promising and 
innovative approach to exploit the intrinsic ability of the adult brain to regenerate in acute and 
chronic neurodegenerative disorders. 
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Figure legends 
Fig. 1 
Schematic representation of the two neurogenic protocols utilized in this study (see text for details 
and drug concentrations). In neurogenic protocol #1 (a; [7]), pharmacological treatments were 
performed during phase C, whereas in neurogenic protocol #2 (b; [27]) exposure to the selected 
drugs was started at the beginning of phase DM up to the end of the experimental protocol. PM: 
proliferation medium; DM: differentiation medium; SCM: stem cell medium; VPA: valproic acid; 
Cang: Cangrelor; UDP-glc; UDP-glucose  
 
Fig. 2 
VPA does not promote the generation of βIII-tubulin+ neurons from OPCs grown in standard 
differentiating conditions. (a, b, c) Histograms showing the number of βIII-tubulin+ cells (a), the 
total number of cells (as evaluated by counting Hoechst33258-stained nuclei; b), and the percentage 
of βIII-tubulin+ cells over the total cell population (c) in OPC cultures grown under standard 
differentiating conditions for 1-3 days. Cultures have been grown either under control condition 
(CTR) or exposed to 500 µM VPA. Results are the mean of 3 coverslips/condition from 1 
representative experiment. *p<0.05 compared to CTR, unpaired two-tailed Students’ t test 
 
Fig. 3  
Generation of βIII-tubulin+ cells by exposing NG2+ OPCs to neurogenic protocol #1. (a) 
Histograms showing the number of cells expressing the cell markers NG2, GFAP, and GPR17 at 
the end of the three phases of neurogenic protocol #1 (data are the mean of 3-10 coverslips from 2-5 
independent experiments; §§p<0.01 compared to phase A; **p<0.01 compared to phase B; One-
way ANOVA Bonferroni post hoc test). (b) Pie charts showing the percentage of NG2-GPR17 
double-positive cells over the total number of GPR17+ cells at the end of phases A and C. Data are 
the mean of 4-7 coverslips from 2-3 independent experiments. A representative image showing the 
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co-localization of GPR17 (green) and NG2 (red) at the end of phase A is shown on the right. Scale 
bar: 100 µm. (c, d) Representative images of the progeny of NG2+ cells at the end of phases B and 
C. Arrow in d indicates a typical βIII-tubulin+ (βIII-tub) neuroblast, which does not co-express 
NG2 (see split fluorescence channels in Supplementary Fig. 1). Scale bars: 100 µm. e) The graph 
shows the percentage of βIII-tub+ cells at the end of each phase of neurogenic protocol #1  
 
Fig. 4 
 In neurogenic protocol #2, incubation in stem cell medium (SCM) “per se” stimulates the 
generation of βIII-tubulin+ cells. (a, b) Histograms showing the percentage of βIII-tubulin+ (βIII-
tub; a) or GPR17+ and NG2+ (b) cells at the end of phase DM or phase SCM (see Figure 1b; 
*p<0.05, and **p<0.01 unpaired two-tailed Student's t test, data are the mean of 3-10 coverslips 
from 2-4 independent experiments). (c) Pie chart showing the percentage of GPR17+ cells co-
expressing NG2 over the total population of GPR17+ cells at the end of phase DM. Data are the 
mean of 7 coverslips from 4 independent experiments 
 
Fig. 5  
In both neurogenic protocols, exposure to VPA fosters the generation of βIII-tubulin+ neurons, in 
parallel with a decreased expression of GPR17. (a) Histograms showing the effect of the treatment 
with VPA on the percentage of GPR17and βIII-tub+ cells at the end of the two neurogenic 
protocols. Data are the mean of 12-20 coverslips from 5-10 independent experiments. *p<0.05, 
**p<0.01 unpaired two-tailed Student’s t-test. (b) Western blotting analysis of the expression of the 
neuronal proteins βIII-tub, synaptic vesicles 2 (SV2), and synaptotagmin (syt), of GPR17 and of the 
mature oligodendrocyte marker CNPase in cell cultures grown under control (CTR) condition or 
after VPA treatment in neurogenic protocol #1 (left) or #2 (right). β-actin is shown as internal 
loading control. One representative experiment out of 3 is shown. (c) Representative images of 
GPR17 expression in OPC cultures grown in standard differentiating medium under control 
 31	
condition (CTR) or after a 24-hour treatment with VPA. Scale bars: 100 µm. Histograms show the 
quantification of GPR17 expression measured as integrated density and expressed as arbitrary unit. 
Data are the mean of 3 coverslips/condition from 1 representative experiment, and are shown as 
mean percentage ± SEM of CTR values set to 100%. *p<0.05 compared to CTR, unpaired two-
tailed Students’ t test. (d) Effect of VPA treatment on GPR17 promoter activity in Oli-neu cells. 
Luciferase activity was normalized to the cells transfected with the empty vector (*p<0.05 unpaired 
two-tailed Students’ t test). (e, f) Histograms showing the effect of the treatment with Cang or 
UDP-glc on the percentage of GPR17+, and βIII-tub+ cells at the end of the neurogenic protocol #1 
(e) or #2 (f). Data are the mean of 9-7 coverslips from 3 independent experiments. *p<0.05 
unpaired, two-tailed Student’s t-test 
 
Fig. 6  
VPA expands the percentage of GPR17+ cells also expressing βIII-tubulin in both neurogenic 
protocols. Representative pictures of cells grown according to neurogenic protocol #1 (a) or #2 (b) 
under the various experimental conditions. Arrows indicate “hybrid” GPR17/βIII-tub double 
positive cells. Scale bars: 100 µm. (c) Histograms showing the percentage of GPR17/bIII-tub 
double-positive cells over the total number of GPR17+ cells at the end of neurogenic protocol #1. 
Results are the mean of 11-16 coverslips from 5-10 independent experiments. Neurogenic protocol 
#1: *p<0.05 CTR vs Cang; **p<0.01 CTR vs VPA unpaired two-tailed Student’s t-test. A non-
significant trend to increase by VPA was observed in neurogenic protocol #2 (d). (e, f) The 
percentage of GPR17/βIII-tub double positive cells over the total number of βIII-tub+ cells is not 
modified by the different pharmacological treatments. 
In the case of neurogenic protocol #1, since the various drugs have been tested in separate 
experiments, the corresponding CTR values are reported for each pharmacological treatment (see 
panels c and e). 
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Supplementary Fig. 1: Split fluorescence channels relative to
picture in Figure 3D, showing that a typical bipolar βIII-tubulin-
positive cell (arrow; βIII-tub, red in a and c) does not express NG2
(green in b and c). Scale bars: 100 μm.
